Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Molecular Partners AG (MOLN)

Compare
3.8400
-0.2300
(-5.65%)
At close: April 1 at 4:00:00 PM EDT
3.8950
+0.06
+(1.43%)
After hours: April 1 at 4:05:09 PM EDT
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
4,970
4,970
7,038
189,556
9,330
Operating Expense
66,187
66,187
68,146
72,943
72,749
Operating Income
-61,217
-61,217
-61,108
116,613
-63,419
Net Non Operating Interest Income Expense
3,346
3,346
4,230
523
-457
Other Income Expense
3,830
3,830
-5,106
717
92
Pretax Income
-54,041
-54,041
-61,984
117,853
-63,783
Tax Provision
2
2
--
--
2
Net Income Common Stockholders
-54,043
-54,043
-61,984
117,853
-63,785
Diluted NI Available to Com Stockholders
-54,043
-54,043
-61,984
117,853
-63,785
Basic EPS
-1.89
-1.59
-1.89
3.63
-2.06
Diluted EPS
-1.89
-1.59
-1.89
3.54
-2.06
Basic Average Shares
33,025.4010
34,032.5440
32,770.6650
32,469.9570
31,005.1710
Diluted Average Shares
33,025.4010
34,032.5440
32,770.6650
33,265.5670
31,005.1710
Total Operating Income as Reported
-61,217
-61,217
-61,108
116,613
-63,418
Total Expenses
66,187
66,187
68,146
72,943
72,749
Net Income from Continuing & Discontinued Operation
-54,043
-54,043
-61,984
117,853
-63,785
Normalized Income
-57,547.4500
-57,547.4500
-56,878
117,136
-63,863.2644
Interest Income
3,384
3,384
4,279
1,142
99
Interest Expense
25
25
34
605
548
Net Interest Income
3,346
3,346
4,230
523
-457
EBIT
-54,016
-54,016
-61,950
118,458
-63,235
EBITDA
-51,647
-51,647
-59,530
120,846
-60,670
Reconciled Depreciation
2,369
2,369
2,420
2,388
2,565
Net Income from Continuing Operation Net Minority Interest
-54,043
-54,043
-61,984
117,853
-63,785
Total Unusual Items Excluding Goodwill
3,830
3,830
-5,106
717
92
Total Unusual Items
3,830
3,830
-5,106
717
92
Normalized EBITDA
-55,477
-55,477
-54,424
120,129
-60,762
Tax Rate for Calcs
0.0001
0.0001
--
--
0.0001
Tax Effect of Unusual Items
325.5500
325.5500
--
--
13.7356
12/31/2021 - 6/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BCAX Bicara Therapeutics Inc.
12.66
-2.84%
 
AVBP ArriVent BioPharma, Inc.
18.03
-2.49%
 
ATXS Astria Therapeutics, Inc.
5.40
+1.12%
 
IDIA.SW Idorsia Ltd
1.0800
+5.99%
 
CANTA.ST Cantargia AB (publ)
1.4300
-1.31%
 
FHTX Foghorn Therapeutics Inc.
3.3750
-7.53%
 
NWRN.SW Newron Pharmaceuticals S.p.A.
7.55
-3.21%
 
COGT Cogent Biosciences, Inc.
5.79
-3.34%
 
YMAB Y-mAbs Therapeutics, Inc.
4.5000
+1.58%
 
ORKA Oruka Therapeutics, Inc.
9.56
-6.82%